Design Therapeutics: 'Hold' DT-216P2 Registrational FA Plans Q4 2026 And 12-Week Results Q1 2027Seeking Alpha · Oct 4, 2026
Design Therapeutics, Inc. (NASDAQ:DSGN) Stock Now Rated “Moderate Buy” by Sell-Side AnalystsDefense World · Sep 30, 2026
Bank of New York Mellon Corp Purchases New Stake in Design Therapeutics, Inc. $DSGNDefense World · Sep 10, 2026
Design Therapeutics to Participate in 2026 Cantor Fitzgerald Global Healthcare ConferenceGlobeNewsWire · Sep 2, 2026
BlackRock Inc. Takes Position in Design Therapeutics, Inc. $DSGNDefense World · Sep 2, 2026
Wall Street Moves on MAA, Rivian and Design Therapeutics: One Upgrade, One Target Trim and a Biotech on Watch24/7 Wall Street · Aug 27, 2026Design Therapeutics, Inc. is a biopharmaceutical company in the preclinical phase that focuses on creating treatments for genetic conditions stemming from nucleotide repeat expansions. Its current pipeline targets Friedreich's Ataxia (FA), a severe, progressive, monogenic, and autosomal recessive disease. FA primarily impairs mitochondrial function across various organ systems, resulting in neurological, cardiac, and metabolic complications.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 3, 2026 | -$0.34 | -$0.32 | Beat |
| Apr 28, 2026 | -$0.36 | -$0.29 | Beat |
| Mar 9, 2026 | -$0.38 | -$0.27 | Beat |
| Nov 5, 2025 | -$0.34 | -$0.30 | Beat |
| Aug 7, 2025 | -$0.32 | -$0.34 | Miss |
| May 7, 2025 | -$0.28 | -$0.31 | Miss |